We would like to encourage you to submit to Frontiers journals your potential manuscripts focusing on novel treatment approaches in Enterobacteriaceae and / or their resistance to antimicrobial agents. Authors may consider treatment of Enterobacteriaceae infections in animals and / or humans. Also antimicrobial resistance to various antimicrobials and implicated encoding genes in Enterobacteriaceae obtained from animals, food and clinical specimens may be considered. Novel treatment approchaes as for E. coli 0157:H7 and E. coli 0104:H4 as well as any other Enterobacteriaceae are welcome. Organisms of the Salmonella, Shigella and E. coli species in addition to many other Enterobacteriaceaea are spread worldwide and the diseases they cause may be fatal especially in immunocompromised patients. Moreover, the high prevalence of ESBL producing Salmonella and Shigella species diseases in different regions suggests major underlying safety issues. According to the World Health Organization (WHO), approximately 2 million individuals worldwide died in 2005 due to diarrheal infections from poultry. As a result, the increase in single or multi drug-resistant foodborne bacterial pathogens is of major public health concern. Moreover, resistance to antimicrobials was found among Salmonella spp and Campylobacter spp from animals and food, and since fluoroquinolones became licensed for use in food animals, especially in poultry, the rate of fluoroquinolone resistant Salmonella spp and Campylobacter spp in animals and food, and then in human infections, rapidly increased. Therefore, the findings of the conducted studies in the potential manuscripts to be submitted must reflect surveillance studies following methodological steps of data collection, analysis and reporting processes that quantitatively monitors temporal trends in the occurrence and distribution of resistance to antimicrobial agents, to third generation cephalosporins, carbapenems, fluoroquinolones and othere and provides information useful as a guide to medical practice, including therapeutics and disease control activities. Moreover, the manuscripts need to reflect an understanding of the mechanisms of transmission of resistance determinants at the molecular level in organisms resistant to one or more antimicrobial agents from animals, food products and clinical specimens in a given setting to allow implementation of appropriate measures to control the spread of determinants of resistance. The manuscripts have to be focused and deal with one or more aspect of what is stated and discussed above.
To view submissions through Frontiers in Cellular and Infection Microbiology, please click here:
http://journal.frontiersin.org/researchtopic/1940/emerging-enterobacteriaceae-infections-antibiotic-resistance-and-novel-treatment-options
We would like to encourage you to submit to Frontiers journals your potential manuscripts focusing on novel treatment approaches in Enterobacteriaceae and / or their resistance to antimicrobial agents. Authors may consider treatment of Enterobacteriaceae infections in animals and / or humans. Also antimicrobial resistance to various antimicrobials and implicated encoding genes in Enterobacteriaceae obtained from animals, food and clinical specimens may be considered. Novel treatment approchaes as for E. coli 0157:H7 and E. coli 0104:H4 as well as any other Enterobacteriaceae are welcome. Organisms of the Salmonella, Shigella and E. coli species in addition to many other Enterobacteriaceaea are spread worldwide and the diseases they cause may be fatal especially in immunocompromised patients. Moreover, the high prevalence of ESBL producing Salmonella and Shigella species diseases in different regions suggests major underlying safety issues. According to the World Health Organization (WHO), approximately 2 million individuals worldwide died in 2005 due to diarrheal infections from poultry. As a result, the increase in single or multi drug-resistant foodborne bacterial pathogens is of major public health concern. Moreover, resistance to antimicrobials was found among Salmonella spp and Campylobacter spp from animals and food, and since fluoroquinolones became licensed for use in food animals, especially in poultry, the rate of fluoroquinolone resistant Salmonella spp and Campylobacter spp in animals and food, and then in human infections, rapidly increased. Therefore, the findings of the conducted studies in the potential manuscripts to be submitted must reflect surveillance studies following methodological steps of data collection, analysis and reporting processes that quantitatively monitors temporal trends in the occurrence and distribution of resistance to antimicrobial agents, to third generation cephalosporins, carbapenems, fluoroquinolones and othere and provides information useful as a guide to medical practice, including therapeutics and disease control activities. Moreover, the manuscripts need to reflect an understanding of the mechanisms of transmission of resistance determinants at the molecular level in organisms resistant to one or more antimicrobial agents from animals, food products and clinical specimens in a given setting to allow implementation of appropriate measures to control the spread of determinants of resistance. The manuscripts have to be focused and deal with one or more aspect of what is stated and discussed above.
To view submissions through Frontiers in Cellular and Infection Microbiology, please click here:
http://journal.frontiersin.org/researchtopic/1940/emerging-enterobacteriaceae-infections-antibiotic-resistance-and-novel-treatment-options
